References
- Smith V, Walton S. Treatment of facial basal cell carcinoma: a review. J Skin Cancer 2011; (E-pub). doi:10.1155/2011/380371
- Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999;135(10):1177–1183
- Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthal Plast Reconstr Surg 2010;26(2):100–102
- Garcia-Martin E, Idoipe M, Gil LM, et al. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. J Ocul Pharmacol Ther 2010;26(4):373–379
- Vun Y, Siller G. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 2006;47(3):169–171
- Cannon PS, O'Donnell B, Huilgol SC, Selva D. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions. Br J Ophthalmol 2011;95(12):1682–1685
- Van der Geer S, Martens J, van Roij J, et al. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. Br J Dermatol 2012;167(1):110–115
- Torres A, Niemeyer A, Berkes B, et al. 5% Imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg 2004;30:1462–1469